Molecular and Virological Effects of Intracellular Anti-Rev Single-Chain Variable Fragments on the Expression of Various Human Immunodeficiency Virus-1 Strains

Publisher Website
Google Scholar
Abstract
A variety of genetic therapies or intracellular immunization techniques hold promise as modalities to inhibit human immunodeficiency virus type 1 (HIV-1) replication in vivo. We have recently demonstrated that a single-chain variable fragment (SFv) construct, derived from a monoclonal antibody that binds to the HIV-1 regulatory protein Rev, can be expressed intracellularly and potently inhibits HIV-1 replication. This single-chain intracellular antibody, which avidly binds to the effector domain of Rev, is now demonstrated to dramatically inhibit various diverse laboratory and primary clinical strains of HIV-1. Potent suppression of HIV-1 replication by this modality is maintained over several months in long-term cultures. As well, the intracellular expression of anti-Rev SFv is shown to alter HIV-1 replication by specifically affecting Rev function. Importantly, no alterations in HIV-1 internalization, reverse transcription, or initial transcription of multiply spliced viral mRNAs are demonstrated in SFv-immunized cells, as compared to controls. Thus, these studies extend the understanding of the molecular mechanisms involved in the inhibition of lentivirus replication, by these intracellular antibody constructs. Intracellular expression of SFv, which bind to the HIV-1 regulatory protein Rev, strongly inhibit multiple divergent strains of HIV-1 in human cells. This antiviral effect is demonstrated to be sustained over several months, and is based on specific inhibition of Rev function, in the retroviral life cycle.